Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Dynavax Technologies Corporation announced that the first participant has been dosed in a Phase II clinical trial evaluating the immunogenicity, safety, and tolerability of the JPEO-CBRND’s Recombinant Plague vaccine combined with Dynavax’s CpG 1018® adjuvant, in adults 18 to 55 years of age.